Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 92

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 92
---
On June 11, 2025, we received
a Bid Price Requirement Letter notifying us that, for the 30 consecutive business day period between April 25, 2025 through June 9, 2025,
the closing bid price for our Common Stock was below the minimum $1.00 per share required for continued listing on The Nasdaq Capital
Market set forth in Nasdaq Listing Rule 5550(a)(2), which is required for continued listing of the Common Stock on Nasdaq. We timely appealed
the delisting determination by requesting a hearing before the Nasdaq Panel. Such request for a Nasdaq Panel hearing stayed the suspension
of the Company’s securities. On July 7, 2025, Nasdaq informed us that they had determined that we have regained compliance with
the Bid Price Requirement and were therefore in compliance with the continued listing requirements. As a result, Nasdaq canceled the hearing
and the Common Stock will continue to be listed and traded on the Nasdaq Capital Market, subject to maintaining all listing standards.

On August 28, 2025, we received a letter from
the staff at the Nasdaq Listing Qualifications department notifying us that such staff had determined that we do not comply with the Stockholders’
Equity Requirement. We previously had been out of compliance with Nasdaq continued listing requirements until, on May 7, 2025, we received
a determination of a Nasdaq hearings panel (a “Hearings Panel”) that we had regained compliance with such requirements. Accordingly,
pursuant to Nasdaq Rule 5815(d)(4)(B), we are subject to a mandatory hearings panel monitor until one year after regaining compliance
with such requirements. As a result, Nasdaq staff lack the discretion to grant us a cure period for demonstrating regaining compliance
with the Stockholders’ Equity Requirement. The Nasdaq staff indicated that our securities would be suspended from trading on Nasdaq
and delisted on September 8, 2025, subject to our right to appeal described below.

On September 3, 2025, we
requested a hearing to appeal such determination before the Hearings Panel. The hearing request stayed the suspension of the trading of
our Common Stock and delisting thereof pending such hearing or any extension provided by the Hearings Panel. The hearing was held on October
14, 2025.

On October 29, 2025, we received the determination
of the Nasdaq Hearings Panel (the “Panel